GR990100388A - PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE.... - Google Patents

PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE....

Info

Publication number
GR990100388A
GR990100388A GR990100388A GR990100388A GR990100388A GR 990100388 A GR990100388 A GR 990100388A GR 990100388 A GR990100388 A GR 990100388A GR 990100388 A GR990100388 A GR 990100388A GR 990100388 A GR990100388 A GR 990100388A
Authority
GR
Greece
Prior art keywords
combination
treatment
compliance
fibrate
statin
Prior art date
Application number
GR990100388A
Other languages
Greek (el)
Inventor
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Publication of GR990100388A publication Critical patent/GR990100388A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical combination comprising an inhibitor of the enzyme 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase (statin), which is simvastatin, fluvastatin,a torvastatin or cerivastatin and a fibric acid derivative (fibrate), which is fenofibrate, ciprofibrate or bezafibrate, and to a method of administering these medicaments for the treatment of dyslipidemia (especially mixed hyperlipidemia and familial combined hyperlipidemia) in diabetics and non-diabetics.According to the method claimed herein, separate dosage forms of statin-fibrate combinations properly ordered in a common blister card or a dispenser releasing one-tablet-per-day could be an effective approach for the treatment at different days of dyslipidemia, providing for patient's compliance, efficacy in normalising lipid parameters, safety in terms of myopathy and lower cost, as compared to conventional every day treatment.Selection of the statin and the fibrate for combination should depend both on pharmacokinetic (or the formulation characteristics of each drug) and pharmacodynamic properties of drugs. Regarding pharmacokinetic properties, each drug of the combination should eliminate during the day of treatment. In this order, interactions of each other should be avoided. Relating to pharmacodynamic properties, most suitable statin for the combination is one that effectively lowers LDL-cholesterol but also lowers triglycerides. Respectively, most suitable fibrate for the combination is one that effectively lowers triglycerides and raises HDL-cholesterol but also lowers LDL-cholesterol to a certain degree. A combination comprising a statin and a fibrate with pharmacodynamic properties complementry to each other should provide for efficacy at different days of treatment comparable to the efficacy of conventional everyday treatment with the same combination.
GR990100388A 1999-11-09 1999-11-09 PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE.... GR990100388A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR99100388 1999-11-09

Publications (1)

Publication Number Publication Date
GR990100388A true GR990100388A (en) 2001-07-31

Family

ID=10943967

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990100388A GR990100388A (en) 1999-11-09 1999-11-09 PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE....

Country Status (3)

Country Link
AU (1) AU1166101A (en)
GR (1) GR990100388A (en)
WO (1) WO2001037831A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030076715A (en) * 2001-03-01 2003-09-26 그레랑 파마수티컬 가부시키가이샤 Fenofibrate containing composition
CA2456732C (en) 2001-08-07 2012-10-30 Galephar M/F Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
DE10200138A1 (en) * 2002-01-04 2003-07-17 Karl Winkler Composition, useful for the treatment of the atherogenic lipid phenotype found in e.g. type II diabetics, comprises agonist of peroxisome proliferator-activated receptor and inducer of low density lipoprotein receptor
DK1599468T3 (en) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders associated therewith such as diabetes and hyperglycemia
EP2287166A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
ATE428411T1 (en) 2003-11-07 2009-05-15 Jj Pharma Inc HDL-BOOSTING COMBINATION THERAPY COMPLEXES
JP2008509154A (en) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド Novel statin drug compositions and related treatment methods
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX2013006332A (en) * 2013-06-05 2014-12-19 Alparis Sa De Cv Oral pharmaceutical compositions for use in dyslipidemias.
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
KR20190116416A (en) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. Compounds and Methods for Treating Primary Bile Cholangitis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M.D.FEHER E.A.: "Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease", BRITISH HEART JOURNAL, vol. 74, no. 1, 1995, pages 14 - 17, XP000925445 *
M.KAYIKCIOGLU E.A.: "A new combination regimen in patients with refractory mixed hyperlipidaemia: alternate day therapy", EUROPEAN HEART JOURNAL, vol. 19, no. supp, 1998, pages 572, XP000925440 *
R.L.B.ELLEN, R.MCPHERSON: "Long-term efficacy and safety of fenofibrate and statin in the treatment of combined hyperlipidemia", AMERICAN JOURNAL OF CARDIOLOGY, vol. 81, no. 4A, 1998, pages 60B - 65B, XP000925448 *

Also Published As

Publication number Publication date
WO2001037831A1 (en) 2001-05-31
AU1166101A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
GR990100388A (en) PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE....
NZ527408A (en) Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
WO2001068096A2 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
JP2005532338A5 (en)
US9642860B2 (en) Combinations of corroles and statins
US20110275649A1 (en) Combination therapy for the prevention of statin induced diabetes
HUP0105019A2 (en) Use of cholesterol-lowering agent
RU2007148908A (en) COMPOSITIONS FOR REDUCING THE RISK OF ARCTHYME CAUSED BY MEDICINES
SK286260B6 (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
CN100528164C (en) Statin therapy for enhancing cognitive maintenance
EP1663247B1 (en) Use of oxcarbazepine for the improvement of sleep in patients suffering from chronic pain
ATE400256T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A CATIONIC EXCIPIENT
CA2375378C (en) Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
US20030119892A1 (en) Methods and compositions for treating headache pain with topical NSAID compositions
AU2017299587B2 (en) Methods and compositions for alleviating myopathy
Chrysant et al. Niacin‐ER/statin combination for the treatment of dyslipidemia: focus on low high‐density lipoprotein cholesterol
Mann Rosuvastatin
WO2007069033A3 (en) Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol
Patel et al. Chemistry of four membered heterocyclic ezetimibe as lipid lowering agent
Stein et al. Insights into statin treatment of hypertriglyceridemia
Ducobu et al. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study
US20080146534A1 (en) Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases
Hamilton-Craig et al. Statin-fibrate combination therapy
Negi Extent and pattern of use of statins and ezetimibe as lipid lowering agents and their influence on marketing strategies
IL310115A (en) Treatment of his hyporesponders

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees